Purpose of this Study
If you choose to join this study, you will:
- Get a random (50:50 chance) assignment to either get the vaccine or a placebo (inactive substance with no drug in it)
- Have blood draws
- Visit our clinic in RTP up to 4 times over the course of about 6 months
Who Can Participate?
Eligibility
Adults ages 50-64 who:
- Are in good general health
- Have not made any changes to their medications for the past 6 weeks
- Do not have any of the following medical conditions: cancer, chronic kidney disease, liver disease, diabetes, HIV, heart disease, or lung disease (including asthma)
- Have smoked fewer than 100 cigarettes in their lifetime
Age Range
50-64
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
Yes
What is Involved?
Description
We are doing this study to learn more about how a COVID-19 vaccine works in adults between the ages of 50 and 64. The study vaccine is the most recent version of Biontech and Pfizer's BNT162b2 vaccine, which is approved by the FDA.
Locations
Other
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
No
Study Details
Full Title
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL STUDY EVALUATING THE SAFETY, TOLERABILITY, IMMUNOGENICITY AND EFFICACY OF A VARIANT-ADAPTED BNT162b2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE
Study Website
Principal Investigator
Emmanuel
Walter
Protocol Number
PRO00119276
NCT ID
NCT07300839
Phase
III
Enrollment Status
Open to Enrollment